KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.
Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...
ABP News on MSN
ABP Live Doc Talk | The silent progression of gallbladder cancer: Why early screening matters more than ever
Gallbladder cancer is a challenge because of its subtle progression and its tendency to escape early detection. Although it is a relatively rare form of cancer, it is often not diagnosed until it ...
Neoadjuvant sacituzumab govitecan plus pembrolizumab achieved a 39% clinical complete response requiring concordant radiographic negativity and pathologic clearance ...
The FDA has acknowledged receipt of the supplemental Biologics License Application (sBLA) for nogapendekin alfa inbakicept-pmln (Anktiva) plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive ...
Investigators sought to determine if the gemcitabine intravesical system plus intravenous cetrelimab could improve survival for patients with muscle-invasive bladder cancer who did not receive radical ...
Colorblindness may be doing more than making traffic lights confusing — it could also be hiding a life-threatening warning sign. Researchers analyzing millions of medical records found that people ...
The authors have declared no conflicts of interest. The patient provided informed consent for the publication of this case report. Acknowledgements: Gupta was involved in writing the original draft, ...
Nurses and advanced practice registered nurses (APRNs) play a central role in preventive care, screening, chronic disease management, and patient education. Expanding this workforce is particularly ...
ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...
Investigators are exploring whether combinational therapies can improve survival for patients with renal cell carcinoma or muscle-invasive bladder cancer.
Theralase Technologies (TSXV:TLT) has shown in pre-clinical trials that its flagship Rutherrin, when activated by X-Ray, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results